Diabetic Retinopathy Market Size, By Type (Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy), By Management (Anti VEGF Drug, Intra-ocular Steroid Injections, Laser Surgeries, Vitrectomy), Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, Japan, China, Brazil and South Africa) Application Potential, Price Trends, Competitive Market Share & Forecast, 2017 - 2024

Choose Licence

 

Diabetic Retinopathy Market size is set to exceed USD 11 billion by 2024; according to a new research report by Global Market Insights. Increasing geriatric population base coupled with rising incidences of age related macular degeneration (AMD) and diabetes will drive diabetic retinopathy market over the coming years. Technological advancements pertaining to diabetic retinopathy treatment and increasing research activities towards developing innovative products for treating vision loss due to diabetes will fuel market growth. Numerous efforts made by organizations such as Canadian Diabetes Association to provide guidelines for diabetic retinopathy screening to patients suffering from diabetes will favor industry growth. Diabetic eye screening program, and other awareness campaigns arranged by government to reduce disease prevalence will further propel industry growth. Urbanization, unhealthy eating habits and physical inactivity has surged number of people suffering from chronic conditions such as diabetes. Factors such as prolonged undiagnosed diabetes, ignorance towards treatment and uncontrolled glucose levels will accelerate incidences of diabetes retinopathy over the coming years. However stringent approval procedure and dearth of skilled ophthalmologists will hinder diabetic retinopathy market growth over the forecast timeframe. Non-proliferative diabetic retinopathy market dominated the market in 2016 and is expected to show considerable growth over the coming years. Rising diabetic population as well as increasing number of people suffering from diabetic retinopathy will drive non-proliferative diabetic retinopathy market. Laser surgery segment is anticipated to witness significant growth over the forecast period due to rising adoption of lasers in various healthcare settings for treatment of diabetic macular edema (DME). Technological advancements in laser treatment to detect eye diseases pre-occurrence of vision loss will further boost market growth. Growing incidences of advanced proliferative diabetic retinopathy will drive vitrectomy segment over the coming years. UK diabetic retinopathy market should witness robust growth over the forecast period. High technological adoption coupled with rising number of people suffering from diabetic retinopathy will drive UK diabetic retinopathy market. Government initiatives including programs such as ?Action for Diabetes? undertaken to aware people about diabetic associated blindness will positively impact industry growth. Growing geriatric population base along with growing prevalence of diabetes will drive Japanese diabetic retinopathy market over the forecast period. Increasing application of vitrectomy for treating diabetic macular edema in the country will further boost market growth. Some of the industry players operating in global diabetic retinopathy market are Allergan, Novartis, Bayer, Genentech and Regeneron Pharmaceuticals. The companies operating in diabetic retinopathy market are focusing on developing new innovative products by adopting strategies such as strategic collaborations, partnerships and acquisition. For instance, Novartis acquired Encore Vision in December 2016 to strengthen its ophthalmic product portfolio. At present, several research projects are being conducted to identify exact inhibitor that leads diabetes to vision loss. Diabetic Retinopathy Market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2012 to 2024, for the following segments: Diabetic Retinopathy Market, By Type Proliferative Non-proliferative Diabetic Retinopathy Market, By Management Anti-VEGF therapy Intraocular steroid injection Laser surgery Vitrectomy The above information is provided for the following regions and countries: North America U.S. Canada Europe UK Germany Asia Pacific Japan China Latin America Brazil Middle East and Africa South Africa

 

Report Content Chapter 1 Methodology & Scope 1.1. Methodology 1.1.1. Initial data exploration 1.1.2. Statistical model and forecast 1.1.3. Industry insights and validation 1.1.4. Market definition and forecast parameters 1.2. Data Sources 1.2.1. Secondary 1.2.2. Primary Chapter 2. Executive Summary 2.1. Diabetic retinopathy industry 360 degree synopsis, 2012 - 2024 2.1.1. Business trends 2.1.2. Type trends 2.1.3. Management trends 2.1.4. Regional trends Chapter 3. Diabetic Retinopathy Industry Insights 3.1. Industry segmentation 3.2. Industry landscape, 2012 - 2024 3.3. Industry impact forces 3.3.1. Growth drivers 3.3.1.1. Growing geriatric population 3.3.1.2. High prevalence of diabetes 3.3.1.3. Increasing occurrence of blindness due to diabetes 3.3.1.4. Large patient population 3.3.2. Industry pitfalls & challenges 3.3.2.1. Dearth of trained ophthalmologists 3.3.2.2. Extensive time for approval of drugs 3.4. Growth potential analysis 3.4.1. By type 3.4.2. By management 3.5. Porter's analysis 3.6. Competitive landscape, 2016 3.6.1. Strategy dashboard 3.7. PESTEL analysis 3.8. Diabetic retinopathy epidemiology 3.8.1. U.S. 3.8.2. Germany 3.8.3. UK 3.8.4. China 3.9. Diabetic retinopathy pipeline Chapter 4. Diabetic Retinopathy Market, By Type 4.1. Global diabetic retinopathy market share, by type, 2016 & 2024 4.2. Proliferative 4.2.1. Market estimates and forecast, by region, 2012 - 2024 4.3. Non-Proliferative 4.3.1. Market estimates and forecast, by region, 2012 - 2024 Chapter 5. Diabetic Retinopathy Market, By Management 5.1. Global diabetic retinopathy market share, by management, 2016 & 2024 5.2. Anti-VEGF therapy 5.2.1. Market estimates and forecast, by region, 2012 - 2024 5.3. Intraocular steroid injection 5.3.1. Market estimates and forecast, by region, 2012 - 2024 5.4. Laser surgery 5.4.1. Market estimates and forecast, by region, 2012 - 2024 5.5. Vitrectomy 5.5.1. Market estimates and forecast, by region, 2012 - 2024 Chapter 6. Diabetic Retinopathy Market, By Region 6.1. Diabetic retinopathy market share, by region, 2016 & 2024 6.2. North America 6.2.1. Market estimates and forecast, by country, 2012 - 2024 6.2.2. Market estimates and forecast, by type, 2012 - 2024 6.2.3. Market estimates and forecast, by management, 2012 - 2024 6.2.4. U.S. 6.2.4.1. Market estimates and forecast, by type, 2012 - 2024 6.2.4.2. Market estimates and forecast, by management, 2012 - 2024 6.2.5. Canada 6.2.5.1. Market estimates and forecast, by type, 2012 - 2024 6.2.5.2. Market estimates and forecast, by management, 2012 - 2024 6.3. Europe 6.3.1. Market estimates and forecast, by country, 2012 - 2024 6.3.2. Market estimates and forecast, by type, 2012 - 2024 6.3.3. Market estimates and forecast, by management, 2012 - 2024 6.3.4. Germany 6.3.4.1. Market estimates and forecast, by type, 2012 - 2024 6.3.4.2. Market estimates and forecast, by management, 2012 - 2024 6.3.5. UK 6.3.5.1. Market estimates and forecast, by type, 2012 - 2024 6.3.5.2. Market estimates and forecast, by management, 2012 - 2024 6.4. Asia Pacific 6.4.1. Market estimates and forecast, by country, 2012 - 2024 6.4.2. Market estimates and forecast, by type, 2012 - 2024 6.4.3. Market estimates and forecast, by management, 2012 - 2024 6.4.4. Japan 6.4.4.1. Market estimates and forecast, by type, 2012 - 2024 6.4.4.2. Market estimates and forecast, by management, 2012 - 2024 6.4.5. China 6.4.5.1. Market estimates and forecast, by type, 2012 - 2024 6.4.5.2. Market estimates and forecast, by management, 2012 - 2024 6.5. Latin America 6.5.1. Market estimates and forecast, by country, 2012 - 2024 6.5.2. Market estimates and forecast, by type, 2012 - 2024 6.5.3. Market estimates and forecast, by management, 2012 - 2024 6.5.4. Brazil 6.5.4.1. Market estimates and forecast, by type, 2012 - 2024 6.5.4.2. Market estimates and forecast, by management, 2012 - 2024 6.6. Middle East & Africa 6.6.1. Market estimates and forecast, by country, 2012 - 2024 6.6.2. Market estimates and forecast, by type, 2012 - 2024 6.6.3. Market estimates and forecast, by management, 2012 - 2024 6.6.4. South Africa 6.6.4.1. Market estimates and forecast, by type, 2012 - 2024 6.6.4.2. Market estimates and forecast, by management, 2012 - 2024 Chapter 7. Company Profiles 7.1. Aerpio Pharmaceuticals 7.1.1. Business overview 7.1.2. Financial data 7.1.3. Product landscape 7.1.4. Strategic outlook 7.1.5. SWOT analysis 7.2. Alimera Sciences, Inc 7.2.1. Business overview 7.2.2. Financial data 7.2.3. Product landscape 7.2.4. Strategic outlook 7.2.5. SWOT analysis 7.3. Allergan PLC (Actavis PLC) 7.3.1. Business overview 7.3.2. Financial data 7.3.3. Product landscape 7.3.4. Strategic outlook 7.3.5. SWOT analysis 7.4. Ampio Pharmaceuticals, Inc. 7.4.1. Business overview 7.4.2. Financial data 7.4.3. Product landscape 7.4.4. Strategic outlook 7.4.5. SWOT analysis 7.5. Bayer AG 7.5.1. Business overview 7.5.2. Financial data 7.5.3. Product landscape 7.5.4. Strategic outlook 7.5.5. SWOT analysis 7.6. BCN Peptides S.A. 7.6.1. Business overview 7.6.2. Financial data 7.6.3. Product landscape 7.6.4. Strategic outlook 7.6.5. SWOT analysis 7.7. Genentech, Inc. 7.7.1. Business overview 7.7.2. Financial data 7.7.3. Product landscape 7.7.4. Strategic outlook 7.7.5. SWOT analysis 7.8. Kowa Company Ltd. 7.8.1. Business overview 7.8.2. Financial data 7.8.3. Product landscape 7.8.4. Strategic outlook 7.8.5. SWOT analysis 7.9. Novartis AG 7.9.1. Business overview 7.9.2. Financial data 7.9.3. Product landscape 7.9.4. Strategic outlook 7.9.5. SWOT analysis 7.10. Regeneron Pharmaceuticals, Inc. 7.10.1. Business overview 7.10.2. Financial data 7.10.3. Product landscape 7.10.4. Strategic outlook 7.10.5. SWOT analysis 7.11. Sirnaomics, Inc. 7.11.1. Business overview 7.11.2. Financial data 7.11.3. Product landscape 7.11.4. Strategic outlook 7.11.5. SWOT analysis 7.12. ThromboGenics 7.12.1. Business overview 7.12.2. Financial data 7.12.3. Product landscape 7.12.4. Strategic outlook 7.12.5. SWOT analysis

Data Tables TABLE 1. Diabetic retinopathy industry 360 degree synopsis, 2012 - 2024 TABLE 2. Global diabetic retinopathy market, 2012-2016 (USD Million) TABLE 3. Global diabetic retinopathy market, 2017-2024 (USD Million) TABLE 4. Global diabetic retinopathy market, by type, 2012 - 2016 (USD Million) TABLE 5. Global diabetic retinopathy market, by type, 2017 - 2024 (USD Million) TABLE 6. Global diabetic retinopathy market, by management, 2012-2016 (USD Million) TABLE 7. Global diabetic retinopathy market, by management, 2017-2024 (USD Million) TABLE 8. Global diabetic retinopathy market, by region, 2012-2016 (USD Million) TABLE 9. Global diabetic retinopathy market, by region, 2017-2024 (USD Million) TABLE 10. Industry impact forces TABLE 11. Lifetime prevalence of diagnosed diabetes mellitus in men(Germany) TABLE 12. Prevalence of different diabetic retinopathy types TABLE 13. Prevalence of diabetic retinopathy in patients with type II diabetes in Europe TABLE 14. Prevalence of diabetes in the adult population across the UK in 2014 TABLE 15. Diabetic retinopathy pipeline TABLE 16. Proliferative market size, by region, 2012-2024 (USD Million) TABLE 17. Non-proliferative market size, by region, 2012-2024 (USD Million) TABLE 18. Anti-VEGF therapy testing market size, by region, 2012-2024 (USD Million) TABLE 19. Intraocular steroid injection market size, by region, 2012-2024 (USD Million) TABLE 20. Laser surgery market size, by region, 2012-2024 (USD Million) TABLE 21. Vitrectomy market size, by region, 2012-2024 (USD Million) TABLE 22. North America diabetic retinopathy market size, by country, 2012 - 2024 (USD Million) TABLE 23. North America diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 24. North America diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 25. U.S. diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 26. U.S. diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 27. Canada diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 28. Canada diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 29. Prevalence of diabetic retinopathy among patients with type II diabetes in European countries TABLE 30. Europe diabetic retinopathy market size, by country, 2012 - 2024 (USD Million) TABLE 31. Europe diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 32. Europe diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 33. UK diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 34. UK diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 35. Germany diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 36. Germany diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 37. Asia Pacific diabetic retinopathy market size, by country, 2012 - 2024 (USD Million) TABLE 38. Asia Pacific diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 39. Asia Pacific diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 40. Japan diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 41. Japan diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 42. China diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 43. China diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 44. Latin America diabetic retinopathy market size, by country, 2012 - 2024 (USD Million) TABLE 45. Latin America diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 46. Latin America diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 47. Brazil diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 48. Brazil diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 49. MEA diabetic retinopathy market size, by country, 2012 - 2024 (USD Million) TABLE 50. MEA diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 51. MEA diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) TABLE 52. South Africa diabetic retinopathy market size, by type, 2012 - 2024 (USD Million) TABLE 53. South Africa diabetic retinopathy market size, by management, 2012 - 2024 (USD Million) Charts & Figures FIG. 1 Industry segmentation FIG. 2 Global diabetic retinopathy market, 2013- 2024 (USD Million) FIG. 3 Growth potential analysis, by type FIG. 4 Growth potential analysis, by management FIG. 5 Porter's analysis FIG. 6 PESTEL analysis FIG. 7 Strategy dashboard FIG. 8 Diabetic retinopathy market share, by type, 2016 & 2024 FIG. 9 Diabetic retinopathy market share, by management, 2016 & 2024 FIG. 10 Diabetic retinopathy market share, by region, 2016 & 2024


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Market Insights, Inc.

New Pharmaceuticals and Healthcare Reports